Charles Schwab Investment Management Inc. Sells 525,408 Shares of bluebird bio, Inc. (NASDAQ:BLUE)

Charles Schwab Investment Management Inc. decreased its holdings in bluebird bio, Inc. (NASDAQ:BLUE - Free Report) by 95.0% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 27,652 shares of the biotechnology company's stock after selling 525,408 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.28% of bluebird bio worth $231,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of BLUE. Barclays PLC lifted its holdings in shares of bluebird bio by 273.7% during the 3rd quarter. Barclays PLC now owns 252,062 shares of the biotechnology company's stock valued at $130,000 after buying an additional 184,605 shares during the period. Geode Capital Management LLC increased its position in bluebird bio by 3.7% during the third quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company's stock valued at $2,433,000 after acquiring an additional 166,771 shares during the last quarter. State Street Corp lifted its holdings in bluebird bio by 1.1% in the third quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company's stock valued at $1,996,000 after acquiring an additional 43,382 shares during the period. Verition Fund Management LLC purchased a new position in bluebird bio in the third quarter worth about $42,000. Finally, Captrust Financial Advisors grew its stake in shares of bluebird bio by 48.2% during the 3rd quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company's stock valued at $123,000 after purchasing an additional 77,293 shares during the period. Institutional investors own 87.43% of the company's stock.

bluebird bio Price Performance

NASDAQ:BLUE traded up $0.06 on Friday, reaching $4.95. 218,782 shares of the company's stock traded hands, compared to its average volume of 382,833. The stock has a 50-day simple moving average of $5.23 and a 200-day simple moving average of $7.51. bluebird bio, Inc. has a 12 month low of $3.56 and a 12 month high of $28.60. The firm has a market cap of $48.46 million, a PE ratio of -0.13 and a beta of 0.41. The company has a quick ratio of 0.33, a current ratio of 0.51 and a debt-to-equity ratio of 0.37.

Wall Street Analysts Forecast Growth

BLUE has been the topic of a number of research reports. StockNews.com started coverage on shares of bluebird bio in a report on Saturday. They issued a "sell" rating on the stock. Wells Fargo & Company cut their price objective on shares of bluebird bio from $40.00 to $5.00 and set an "equal weight" rating for the company in a research report on Monday, February 24th. Barclays decreased their target price on bluebird bio from $40.00 to $8.00 and set an "overweight" rating on the stock in a report on Monday, March 31st. JPMorgan Chase & Co. raised bluebird bio from an "underweight" rating to a "neutral" rating in a report on Monday, February 24th. Finally, Baird R W downgraded bluebird bio from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 21st. One investment analyst has rated the stock with a sell rating, six have given a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $44.60.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.